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Chronic inflammatory demyelinating polyneuropathy as a paraneoplastic manifestation of 
colorectal carcinoma: What do we know? 
The pathogenesis of chronic inflammatory demyelinating poly-
neuropathy (CIDP) remains highly debated among experts. In recent 
times, literature has divulged a riveting yet plausible association be-
tween colorectal carcinoma and CIDP as its paraneoplastic ramification. 
Initially, research suggested that chronic inflammatory demyelinating 
polyneuropathy (CIDP) was caused solely by macrophages [1]. How-
ever, recent studies have insinuated towards an alternative pathogen-
esis, one involving autoantibodies against paranodal junction proteins 
[2]. These two distinct mechanisms are the primary contenders 
responsible for the development of CIDP, rendering it an elusive para-
neoplastic manifestation of colorectal carcinoma. 
Traditionally, macrophages have been purported to be responsible 
for the phagocytosis of the myelin surrounding peripheral neurons [1]. 
A recent study divulged that macrophage-induced demyelination is not 
only responsible for classical CIDP but also atypical CIDP such as distal 
acquired disseminated symmetric (DADS) CIDP, multifocal acquired 
demyelinating sensory and motor (MADSAM) CIDP, and pure sensory 
subtypes [3]. However, of note, this was not found to be true in all cases 
[3]. A teased-fibre preparation of a sural nerve biopsy taken from the 
same patients showed sections without myelin due to 
macrophages-induced phagocytosis [2]. Moreover, electron microscopy 
showed that the macrophages were found within the tubes of basement 
membrane, which itself is normally encompassed by myelin [2]. Yet 
myelin debris was detected in macrophage cytoplasm [2]. On the other 
hand, the cytoplasm of the Schwann cells, found in the outermost layer 
of the myelinated fibers, were intact and unaffected by macrophages 
[2]. 
Factors responsible for the phagocytosis of myelin are still unclear 
[2]. A recent study examining a sural nerve biopsy through an electron 
microscope showed that macrophages tend to target specific sites of the 
myelinated fibers [4]. In particular, the region surrounding the nodes of 
Ranvier and the internodes in certain patients appear to be major sites of 
attack; notably, this is the internal space of the basement membrane, 
which encompasses the myelinated fibers [4]. These findings suggest the 
presence of local factors that differentiate between the nodal and 
internodal region [4]. One possible explanation may be the deposition of 
undiscovered antibodies on the peripheral nerves [4]. When the mac-
rophages detect these antibodies, they activate, triggering myelin 
phagocytosis [4]. In fact, antibodies to a specific peripheral nerve 
glycolipid, sialosylneolactotetraosylceramide (LM1), were detected in 
cases with macrophages-induced demyelination [5]. Moreover, com-
plement (C9) was also found on the myelin. In patients with 
Guillain-Barre syndrome (GBS), macrophage-induced demyelination is 
morphologically identical to patients with CIDP [6]. In the peripheral 
nervous system, foreign epitopes from infectious agents mimic the self 
epitope, which leads to autoantibody production [7]. This concept, 
molecular mimicry, has been proven in GBS [7]. A similar mechanism 
may indeed be responsible for the initial steps of the immunological 
process in CIDP [2]. However, studies have not yet shown a direct as-
sociation between macrophages and autoantibodies apart from the 
study mentioned earlier [5]. Another emerging theory is that of IgG4 
autoantibodies [2]. Studies have shown that in patients with CIPD, 
specific antibodies act on components of the nodes of Ranvier and 
paranodes [4]. Example of these IgG4 autoantibodies include 
anti-contactin-1 and anti-neurofascin-155 antibodies, which target the 
paranodal junction between axolemma and the myelin terminal loops 
[8]. Patients with these antibodies have been found to have distinct 
clinical features including tremor and sensory ataxia, as well as being 
unresponsive to intravenous immunoglobulin [9]. A sural nerve biopsy 
that contained anti-neurofascin-155 and anti-contactin-1 autoantibodies 
showed endoneural edema, decreased density of myelinated fibres due 
to axonal degradation, and a lack of cellular infiltration due to inflam-
mation [10]. These observations are the basis for the alternative path-
ogenesis theory of CIPD [2]. 
CIDP can be divided into a “classical/typical” subtype and into 
atypical subtypes, of which there are many, suggesting that it is a 
spectrum of disease as classified by the European Federation of Neuro-
logical Societies/Peripheral Nerve Society Guidelines on the Manage-
ment of CIDP (EFN/PNS) [11,12]. There are five main subtypes of CIDP; 
predominantly distal (distal acquired demyelinating symmetric 
[DADS]), asymmetrical (multifocal acquired demyelinating sensory and 
motor neuropathy [MADSAM]/Lewis-Sumner syndrome), focal, pure 
motor or pure sensory [12]. Clinically, it is imperative to distinguish 
between classical and atypical phenotypes of the disease as immuno-
suppressive drugs that are effective in typical CIDP demonstrate varying 
responses in atypical phenotypes [13]. Epidemiologically, only 51% of 
patients exhibit the classical phenotype [14]. Patients typically present 
with proximal and distal sensorimotor deficits with demyelination that 
is defined by the EFNS/PNS Criteria [12]. Pathologically, this definition 
includes vertical accumulation of Schwann cell cytoplasmic process, 
resulting in onion-bulb formation, segmental demyelination, and 
mononuclear cell infiltrates [15]. More specifically, 
macrophage-induced demyelination followed by remyelination is 
evident [3]. DADS is an IgM monoclonal protein associated neuropathy 
[15]. Clinically, DADS presents with a distal, symmetric 
sensory-predominant neuropathy that may cause sensory ataxia. Elec-
trophysiology demonstrates abnormally increased distal latencies [16]. 
Although the accepted pathogenesis of classical CIDP and DADS is 
through macrophage-induced demyelination, recent studies also suggest 
that patients with autoantibodies against paranodal junction pro-
teins—specifically contactin 1- and neurofascin 155-IgG4—may also 
present another mechanism by which immune-mediated neuropathies 
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are manifested [3,15]. 
Sensory CIDP commonly presents as a diffuse sensory neuropathy 
with chronic progression. When it is restricted to sensory nerve roots, 
the phenotype is known as chronic immune sensory polyradiculopathy. 
In these cases, electrophysiology studies demonstrate normal motor 
nerve conduction velocities. First-line treatment for pure sensory CIDP is 
immunomodulatory therapy. Notably, it also responds well to IVIG or 
steroids. Therefore, the treatment of pure sensory CIDP is similar to that 
of classical CIDP [13]. However, while pure sensory CIDP itself responds 
to steroids, one study demonstrated that administration of high dose 
steroids in these specific cases may result in unfavorable outcomes. On 
the other hand, pure motor CIDP presents with motor deficits with 
normal sensory nerve conduction velocities [16,17]. In contrast to pure 
sensory CIDP, pure motor CIDP displays an unresponsiveness and even 
potential exacerbation of symptoms when treated with steroids [3]. 
Therefore, IVIG is recommended as first line [13]. Focal CIDP is the least 
common form of atypical CIDP, describing motor or sensorimotor neu-
ropathy confined to one limb [12,13] Focal CIDP may involve nerve 
plexuses or one or more peripheral nerves in an upper or lower limb. 
Treatment of the focal phenotype of CIDP is immunomodulatory therapy 
that may require maintenance therapy [13]. 
Demyelinating neuropathies such as GBS and CIDP have been re-
ported to be associated with haematological malignancies such as 
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). On the 
other hand, GBS and CIDP are rarely associated with solid tumours [18]. 
Within the literature, GBS and CIDP have been reported as a potential 
paraneoplastic neuropathy with carcinoma [19]. For example, Ayyap-
pan et al. described the presentation of atypical CIDP, a distal acquired 
demyelinating symmetric (DADS), as a paraneoplastic syndrome in a 
78-year-old female that was diagnosed with colorectal carcinoma only 
one month after being diagnosed with neuropathy. Her neuropathy was 
characterised by a 4-month history of distal motor and sensory 
involvement, which is typical of DADS. Nerve conduction studies 
confirmed a demyelination neuropathy that was consistent with the 
diagnosis of DADS neuropathy. Moreover, there was an elevated anti-
nuclear antibody (ANA) titre, positive eosinophilia, and positive 
myelin-associated glycoprotein (MAG) IgM antibody by immunofluo-
rescence essay. No treatment was established for her neuropathy due to 
its mild course. After endoscopic diagnosis of her colon adenocarcinoma 
and subsequent tumour resection, there was marked improvement of her 
clinical neuropathy. Follow up nerve conduction studies no longer 
revealed the demyelinating neuropathy and the laboratory studies 
returned a negative anti-MAG antibody and positive ANA. This study 
drew special attention to the importance of taking into consideration the 
paraneoplastic causes in patients diagnosed with subacute neuropathy 
[18]. Notably, there is the possibility that colon cancer and neuropathy 
may coexist by chance in this patient as colon cancer is not an uncom-
mon condition. However, due to the clinical and electrophysiological 
remission of neuropathy following tumour removal, the study argued 
that this DADS neuropathy was very likely presenting as a paraneo-
plastic syndrome related to a tumour-associated immune response [18]. 
In another study, a similar patient was described with a 2-month 
history of acroparesthesias and distal muscle weakness [20]. Nerve 
conduction studies were consistent with demyelination. This patient 
received monthly IVIG for 42 months, with mild improvement. 
Post-therapy, the weakness worsened, and a reduced responsiveness to 
immune therapy was observed. To overcome this, IVIG was combined 
with steroids and plasmapheresis. However, this was also not effective. 
Ten months later, sigmoid colon adenocarcinoma was detected, which 
was duly treated with radical hemicolectomy followed by chemo-
therapy. Unfortunately, the patient died a year after their cancer diag-
nosis. The authors claimed that they were hesitant to consider this 
patient’s DADS neuropathy as a paraneoplastic syndrome. There is thus 
an unmet need for large, randomised controlled trials regarding the 
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